Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDrax Regulatory News (DRX)

Share Price Information for Drax (DRX)

Share Price is delayed by 15 minutes
Get Live Data
756.00    -4.50 (-0.59%)
Bid:
754.50
Ask:
755.50
Spread: 1.00 (0.133%)
Market Cap: £2.54b
DRX Live PriceLast checked at - London Stock Exchange

Intraday Drax Share Chart

New ESG RCF and Financing Update

19 Nov 2020 07:00

RNS Number : 8002F
Drax Group PLC
19 November 2020
 

19 November 2020

Drax Group plc

("Drax", the "Group" or the "Company"; Symbol: DRX)

 

New ESG RCF and Financing Update

 

New Environmental, Social and Governance (ESG) Revolving Credit Facility (RCF)

Drax is pleased to announce that it has completed the refinancing of its revolving credit facility.

 

The new £300 million facility ("the Facility") matures in 2025, with an option to extend by one year(1). The Facility replaces the current RCF which matures in 2021 and provides increased liquidity, enabling the full facility to be drawn as cash (the previous facility restricted cash drawn to support liquidity to £165 million). The Facility is currently undrawn for cash.

 

The Facility has a customary margin grid referenced over LIBOR, which reflects a small reduction in cost versus the current RCF and includes an embedded ESG component which adjusts the margin based on Drax's carbon intensity measured against an annual benchmark.

 

Drax has also agreed a change to the Group's £35 million term-loan facility, maturing in 2022, in order to simplify its capital structure. This facility will now rank as senior, previously super senior.

 

Drawing of previously agreed infrastructure facility

On 14 September 2020, Drax confirmed that it had agreed a new infrastructure term-loan agreement (the "Agreement") that provided committed facilities of approximately £160 million with a range of maturities between 2024 and 2030(2). These facilities extended the Group's maturity profile while also reducing the cost of debt. Drax has now drawn £28 million(2), with the balance to be drawn by February 2021.

 

The Agreement also included an option for a further £75 million. Under this option Drax has now agreed £53 million maturing in 2028, which will be drawn in December 2020.

 

Proceeds from Euro denominated bond issue and utilisation

On 4 November 2020, Drax issued €250 million of Euro denominated senior secured notes which mature in 2025. The effective Sterling-equivalent interest rate is 3.24% per annum.

 

The proceeds from this issuance, along with existing cash flows, are being used to redeem the Group's £350 million 2022 Sterling bond and £125 million ESG term-loan facility.

 

The notes extend the Group's debt maturity profile and reduce the overall cost of debt to approximately 3.7%.

 

Summary of Group debt structure at 19 November 2020

 

Instrument

Maturity

Description

Infrastructure facilities (2019)

 

Infrastructure facilities (Sept 2020)

 

Infrastructure facilities (Nov 2020)

 

2024-2029

 

2024-2030

 

2028

£375m

 

approx.£160m(2) (£28m(2) drawn)

 

£53m

Bonds

 

2025

 

2025

 

$500m

 

€250m

RCF

2025

 

£300m (undrawn for cash)

Index-linked term-loan

2022

 

£35m

 

Enquiries:

Drax Investor Relations: Mark Strafford

+44 (0) 7730 763 949

 

Media:

Drax External Communications: Selina Williams

+44 (0) 7912 230 393

 

Website: www.drax.com

 

END

 

Note

(1) Subject to lender consent.

(2) Approximately £160m - €25 million in 2024, €70 million in 2026, £45 million in 2027 and €31.5 million (£28 million) in 2030. To date Drax has only drawn €31.5 million (£28 million) with the balance to be drawn by February 2021. Drax intends that foreign exchange hedging of Euro denominated proceeds will take place prior to the drawdown of funds.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDGBDBUSBDGGI
Date   Source Headline
18th Jun 20267:00 amRNSClosure of Investigation by the FCA
17th Jun 20269:16 amRNSHolding(s) in Company
16th Jun 202610:00 amRNSDirector Declaration
5th Jun 202610:21 amRNSHolding(s) in Company
1st Jun 202611:02 amRNSIssue of Shares
1st Jun 202610:28 amRNSTotal Voting Rights
1st Jun 20267:47 amRNSDisclosure Table
1st Jun 20267:00 amRNSOffer for Bluefield Solar Income Fund Limited
29th May 20267:00 amRNSCommissioning of First OCGT Plant
27th May 20267:00 amRNSChief Financial Officer
26th May 20268:45 amRNSApplication for block admission to trading
8th May 20269:00 amRNSDirector/PDMR Shareholding
1st May 202610:15 amRNSTotal Voting Rights and Issue of Shares
30th Apr 202612:53 pmRNSResult of AGM
30th Apr 20267:00 amRNSTrading Update
15th Apr 20268:45 amRNSApplication for block admission to trading
10th Apr 20267:00 amRNSTransaction in Own Shares
9th Apr 20267:00 amRNSTransaction in Own Shares
8th Apr 20267:00 amRNSTransaction in Own Shares
7th Apr 20267:00 amRNSTransaction in Own Shares
2nd Apr 20267:00 amRNSTransaction in Own Shares
1st Apr 202612:46 pmRNSTotal Voting Rights
1st Apr 20267:00 amRNSTransaction in Own Shares
31st Mar 202612:09 pmRNSIssue of Shares
31st Mar 20267:00 amRNSTransaction in Own Shares
30th Mar 20267:00 amRNSTransaction in Own Shares
27th Mar 20267:00 amRNSTransaction in Own Shares
26th Mar 20267:00 amRNSTransaction in Own Shares
25th Mar 20269:48 amRNSNotice of AGM and Annual Report and Accounts
25th Mar 20267:00 amRNSTransaction in Own Shares
24th Mar 202610:35 amRNSHolding(s) in Company
24th Mar 20267:00 amRNSTransaction in Own Shares
23rd Mar 20267:00 amRNSTransaction in Own Shares
20th Mar 20267:00 amRNSTransaction in Own Shares
19th Mar 20267:00 amRNSTransaction in Own Shares
18th Mar 20267:00 amRNSTransaction in Own Shares
17th Mar 20264:43 pmRNSDirector/PDMR Shareholding
17th Mar 20267:00 amRNSTransaction in Own Shares
17th Mar 20267:00 amRNSTransaction in Own Shares
16th Mar 20267:00 amRNSTransaction in Own Shares
16th Mar 20267:00 amRNSTransaction in Own Shares
13th Mar 20267:00 amRNSTransaction in Own Shares
13th Mar 20267:00 amRNSTransaction in Own Shares
12th Mar 20267:00 amRNSTransaction in Own Shares
11th Mar 20267:00 amRNSCapacity Market Agreements
11th Mar 20267:00 amRNSTransaction in Own Shares
11th Mar 20267:00 amRNSTransaction in Own Shares
10th Mar 20267:00 amRNSTransaction in Own Shares
10th Mar 20267:00 amRNSTransaction in Own Shares
9th Mar 20267:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.